Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas and currently employs 13 full-time employees. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Follow-Up Questions
CING 주식의 가격 성능은 어떻습니까?
CING의 현재 가격은 $3.69이며, 전 거래일에 decreased 0.08% 하였습니다.
Cingulate Inc의 주요 사업 주제나 업종은 무엇입니까?
Cingulate Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Cingulate Inc의 시가총액은 얼마입니까?
Cingulate Inc의 현재 시가총액은 $20.7M입니다
Cingulate Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 7명의 분석가가 Cingulate Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 7명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
